The company manufacture and markets, generic pharmaceuticals, value added generic pharmaceuticals, branded generics, active Pharmaceuticals (API) and intermediates by using finest R&D and Manufacturing facilities, which was named as Ranbaxy Laboratories Limited (RLL), had its origins in the early 1960s when Ranjit Singh and Gurbux Singh, two employees of a Japanese pharmaceutical company operating in India, formed their own pharmaceutical preparations company in Amritsar, in Punjab state. Two of them merged their names to form the name for their company as Ranbaxy. The company was incorporated in the year 1961 and linked up with a European pharmaceutical company, began production in 1962. Ranbaxy's owners sought additional financing and turned to a local moneylender, Bhai Mohan Singh, by 1966 the lender came to collect, the Ranbaxy partners offered to turn over their company to him instead. After that pathetic situation, Singh agreed to the deal and launched the Ranbaxy family on the path toward building one of India's largest business empires. Under Bhai Mohan Singh, Ranbaxy initially maintained its course of preparing and packing existing branded pharmaceutical products for the Indian market. The entry of Singh's eldest son, Parvinder, into the company in 1967, however, set the company on a new course to become a fully independent pharmaceutical company.
The Company ranked amongst the top ten global generic companies and has a presence in 23 of the top 25-pharma markets of the world. The Company with a global footprint in 49 countries, world-class manufacturing facilities in 11 and a diverse product portfolio, is rapidly moving towards global leadership, riding on its success in the world's emerging and developed markets. Ranbaxy's diverse product basket of over 5,000 SKUs available in over 125 countries worldwide encompasses a wide therapeutic mix covering a majority of the chronic and acute segments.
Ranbaxy is among the few Indian pharmaceutical companies in India to have initiated its research program in the late 1970's. Ranbaxy's good fortune came in 1970, when the Indian government passed legislation that effectively ended patent protection in the pharmaceutical industry. The company expanded quickly, and by 1973, Ranbaxy opened a new factory, in Mohali, for the production of active principal ingredients (APIs) and the company went to public in the same year 1973. To support its global ambition, a first of its kind world class R&D centre was commissioned in the year 1994, which has enabled the company to begin to enter the new chemical entities (NCE) and novel drug delivery systems (NDDS) markets. In 1977 the company begins production in Lagos, Nigeria through a joint venture and in 1983 opens a dosage plant in Dewas. The company builds a state-of-the-art API facility in Toansa in preparation for entry into the U.S. market during the period of 1987. The company's joint marketing agreement was made with Eli Lilly in 1992. A joint venture was launched in China; a new research-driven NCE and NDDS strategy was came to effect on 1993. During 2004-05 the company opens a new research and development facility in Gurgaon, India, the company acquires Ohm Laboratories in the United States and builds a new FDA-approved production facility.
Ranbaxy's own branded drugs were pierced into market in United States and the company got underway-clinical trials on the first in-house developed molecule in the year 1998. Ranbaxy is focused on increasing the momentum in the generics business in its key markets through organic and inorganic growth routes. It continues to evaluate acquisition opportunities in India, emerging and developed markets to accentuate its business and competitiveness. RLL acquired Basics, Bayer's generics business in Germany during the period 2000. The company opened a new manufacturing plant in Vietnam on 2001 and again company acquired RPG (Aventis) in France, becoming the leading generics manufacturer for that market in 2003, it sought new alliances, the company reached a global drug discovery and development partnership with GlaxoSmithKline in the same year. Due to the high demand and expanding nature, the company launched a new production facility in Brazil in 2005 worth of $100 million. In 2006 the company established a wholly owned subsidiary in Sweden under the name of Ranbaxy Pharma AB for manage the operations in the territories of Sweden, Norway, Denmark & Finland and the company has formed a Joint venture in South Africa under the name of Sonke Pharmaceuticals (proprietary) Ltd. RLL acquired Terapia SA (Romania), Ethimed (Belgium), Allen (Italy), Mundogen (Spain) and Sentek PLC's Proprietary Technology and also the company has entered into an agreement for acquisition on 100% Equity stake in Bio-Tabs Pharmaceuticals (Proprietary) Ltd (SA) during the period of 2007.
In January 2008, RLL entered into the Chyawanprash segment, launched its sugar-free product under the Brand name Chyawan Active'. The product marketed by Ranbaxy's Global Consumer Healthcare division, will be initially introduced in North India (Delhi, UP, Punjab and Bihar) and later in other parts of the country. In February of the year the company made De-merger of the Company's New Drug Discovery Research (NDDR) Unit into a subsidiary, Ranbaxy Life Science Research Ltd. (RLSRL). As on April 2008 the Company has received final approval from the U.S. Food and Drug Administration to manufacture and market Cetirizine Hydrochloride Oral Solution (Allergy) and Children's Cetirizine Hydrochloride Oral Solution (Hives-Relief), 1 mg/ml (OTC), Ranbaxy Laboratories Limited (Ranbaxy) and Orchid Chemicals & Pharmaceuticals Limited (Orchid) entered into a business alliance agreement involving multiple geographies and therapies for both finished dosage formulations and active pharmaceutical ingredients. During the same month of the year, the company has pierced into a collaborative research agreement with the Department of Biotechnology (DBT), New Delhi, in the area of New Drug Discovery Research (NDDR). The research will be conducted under the aegis of DBT's major initiative in the area of tuberculosis. The Company has received authorization from Ministry of Health and Labour Welfare (MHLW-Japan) for marketing the generic version of Amlodipine tablets 2.5mg & 5mg and launched BONISTA- Teriparatide injection (recombinant human parathyroid hormone) for the treatment of Osteoporosis, in collaboration with Virchow Biotech Pvt Ltd, Hyderabad, India. Ranbaxy is the first company to launch this bio-generic product in the world.
The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries. RLL working towards achieve excellence and set new global benchmarks. Driven by its vision to become a global leader the Company reinvents itself to achieve sustained growth and leadership in Research-based International Pharmaceutical.